the ‘wonder’ cream is also the first of its kind to have been classified as a Class 1 Medical Device to treat the symptoms of ...

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro ...

Cellulitis is a common bacterial skin infection affecting the dermis and underlying tissues If untreated it can lead to ...

As the seasons change, your skin-care routine might need to change too. Prevent and soothe dry, irritated winter skin with ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.